AstraZeneca PLCAZN:LSE

22.50 / 0.50 %
5.25 %
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Nov 24 2015 16:49 GMT.

Consensus recommendation

As of Nov 21, 2015, the consensus forecast amongst 35 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 18, 2015. The previous consensus forecast advised that AstraZeneca plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Research Reports

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials


In 2014, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 31 analysts covering the company expect dividends of 2.77 USD for the upcoming fiscal year, a decrease of 1.07 %. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Nov 05, 2015, AstraZeneca plc reported 3rd quarter 2015 earnings of 1.03 per share. This result was in line with the consensus of the 14 analysts following the company and under-performed last year's 3rd quarter results by 1.90 %.
The next earnings announcement is expected on Feb 03, 2016. View Full Interim Financials

Average growth rate+2.86 %

AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015.
The next earnings announcement from AstraZeneca plc is expected the week of Feb 03, 2016. View Full Annual Financials

Average growth rate-9.98 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


AstraZeneca PLC had 3rd quarter 2015 revenues of 5.95bn. This missed the 5.97bn consensus estimate of the 15 analysts following the company. This was 9.13 % below the prior year's 3rd quarter results. View Full Interim Financials

Average growth rate-2.21 %

AstraZeneca PLC had revenues for the full year 2014 of 26.10bn. This was 1.49% above the prior year's results. View Full Annual Financials

Average growth rate-5.59 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.